Literature DB >> 12869030

Complement component C7 deficiency in a Spanish family.

M F Vázquez-Bermúdez1, S Barroso, K Walter, A J Alvarez, A Alarcón, M López-Trascasa, I Wichmann, F Aguilar, A Núñez-Roldán, B Sánchez.   

Abstract

Different genetic mutations have been described in complement component C7 deficiency, a molecular defect which is clinically associated with an increased susceptibility to neisserial recurrent infections, although some cases remain asymptomatic. In this work we report the genetic bases of C7 deficiency in one Spanish family. Exon-specific PCR and sequencing revealed a novel point mutation at nucleotide 615 (exon 6) leading to a stop codon (UGG to UGA) in the patient, his mother, and sister. This transversion causes the premature truncation of the C7 protein (W183X). Additionally, we detected a missense mutation at position 1135 (exon 9) located in the first nucleotide of the codon GGG (CGG), resulting in an amino acid change (G357R) in the patient, his father, as well as in his sister. This latter mutation had been previously described in individuals from Moroccan Sephardic Jewish ancestry. Since both heterozygous mutations were found in the patient as well as in his asymptomatic sister, we analyse other meningococcal defence mechanisms such as polymorphisms of the opsonin receptors on polymorphonuclear cells. Results showed that the patient and his sister bore identical combinations of FcgammaRIIA-H/R131 and FcgammaRIIIB-NA1/2 allotypes. Our results provide further evidence that the molecular pathogenesis of C7 deficiency as well as susceptibility to meningococcal disease are heterogeneous, since different families carry different molecular defects, although many of the C7 defects appear to be homogeneous in individuals from certain geographical areas. The missense mutation G357R would make an interesting topic of analysis with regard to meningococcal disease susceptibility in the Spanish population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12869030      PMCID: PMC1808760          DOI: 10.1046/j.1365-2249.2003.02186.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

1.  HLA polymorphism in a Majorcan population of Jewish descent: comparison with Majorca, Minorca, Ibiza (Balearic Islands) and other Jewish communities.

Authors:  C Crespí; J Milà; N Martínez-Pomar; A Etxagibel; I Muñoz-Saa; D Priego; A Luque; J Pons; A Picornell; M Ramon; J A Castro; N Matamoros
Journal:  Tissue Antigens       Date:  2002-10

2.  The structure of human complement component C7 and the C5b-7 complex.

Authors:  R G DiScipio; D N Chakravarti; H J Muller-Eberhard; G H Fey
Journal:  J Biol Chem       Date:  1988-01-05       Impact factor: 5.157

3.  The gene for human complement component C9 mapped to chromosome 5 by polymerase chain reaction.

Authors:  C Abbott; L West; S Povey; S Jeremiah; Z Murad; R DiScipio; G Fey
Journal:  Genomics       Date:  1989-05       Impact factor: 5.736

4.  Relevance of Fcgamma receptor and interleukin-10 polymorphisms for meningococcal disease.

Authors:  W L van der Pol; T W Huizinga; G Vidarsson; M W van der Linden; M D Jansen; V Keijsers; F G de Straat; N A Westerdaal; J G de Winkel; R G Westendorp
Journal:  J Infect Dis       Date:  2001-12-03       Impact factor: 5.226

5.  A comprehensive set of sequence analysis programs for the VAX.

Authors:  J Devereux; P Haeberli; O Smithies
Journal:  Nucleic Acids Res       Date:  1984-01-11       Impact factor: 16.971

6.  High prevalence of complement C7 deficiency among healthy blood donors of Moroccan Jewish ancestry.

Authors:  D Halle; D Elstein; D Geudalia; A Sasson; E Shinar; M Schlesinger; A Zimran
Journal:  Am J Med Genet       Date:  2001-04-01

7.  The role of Fcgamma receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement-deficient individuals.

Authors:  C A Fijen; R G Bredius; E J Kuijper; T A Out; M De Haas; A P De Wit; M R Daha; J G De Winkel
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

Review 8.  Infectious diseases associated with complement deficiencies.

Authors:  J E Figueroa; P Densen
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

9.  A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding.

Authors:  P A Warmerdam; J G van de Winkel; A Vlug; N A Westerdaal; P J Capel
Journal:  J Immunol       Date:  1991-08-15       Impact factor: 5.422

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Deficiencies of the complement MAC II gene cluster (C6, C7, C9): is subtotal C6 deficiency of particular evolutionary benefit?

Authors:  R Würzner
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

2.  Molecular defects of the C7 gene in two patients with complement C7 deficiency.

Authors:  Sonia Barroso; Claudine Rieubland; Antonia José álvarez; Margarita López-Trascasa; Pierre-Alexandre Bart; Antonio Núñez-Roldán; Berta Sánchez
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

3.  Complement component C7 deficiency in two Spanish families.

Authors:  Sonia Barroso; Berta Sánchez; Antonia José Alvarez; Margarita López-Trascasa; Amparo Lanuza; Rafael Luque; Ingeborg Wichmann; Antonio Núñez-Roldán
Journal:  Immunology       Date:  2004-12       Impact factor: 7.397

4.  Two novel mutations in the C7 gene in a Korean patient with complement C7 deficiency.

Authors:  Chang-Seok Ki; Jong-Won Kim; Hee-Jin Kim; Sung-Min Choi; Gyoung-Yim Ha; Hee Jung Kang; Won-Duck Kim
Journal:  J Korean Med Sci       Date:  2005-04       Impact factor: 2.153

5.  Two mutations of the C7 gene, c.1424G > A and c.281-1G > T, in two Korean families.

Authors:  Hee Jung Kang; Chang-Seok Ki; Yeon-Sook Kim; Mina Hur; So Ick Jang; Ki Sik Min
Journal:  J Clin Immunol       Date:  2006-03-22       Impact factor: 8.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.